Anti-viral memory T cell responses in the absence of IgG production in a COVID-19 convalescent individual

Special Topic: COVID-19: Virus, Immunity and Vaccines

Open Access

Issue		Natl Sci Open Volume 1, Number 1, 2022 Special Topic: COVID-19: Virus, Immunity and Vaccines


Article Number		20220009
Number of page(s)		15
Section		Life Sciences and Medicine
DOI		https://doi.org/10.1360/nso/20220009
Published online		24 March 2022

Wang C, Horby PW, Hayden FG et al. A novel coronavirus outbreak of global health concern. Lancet 2020; 395: 470-473. [Article] [CrossRef] [PubMed] [Google Scholar]
Ni L, Ye F, Cheng ML et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 2020; 52: 971-977. [Article] [CrossRef] [PubMed] [Google Scholar]
Grifoni A, Weiskopf D, Ramirez SI et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020; 181: 1489-1501. [Article] [CrossRef] [PubMed] [Google Scholar]
Wu F, Liu M, Wang A et al. Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China. JAMA Intern Med 2020; 180: 1356. [Article] [CrossRef] [PubMed] [Google Scholar]
Ni L, Cheng ML, Feng Y et al. Impaired cellular immunity to SARS-CoV-2 in severe COVID-19 patients. Front Immunol 2021; 12: 603563. [Article] [CrossRef] [PubMed] [Google Scholar]
Rydyznski Moderbacher C, Ramirez SI, Dan JM et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 2020; 183: 996-1012. [Article] [CrossRef] [PubMed] [Google Scholar]
Zuo J, Dowell AC, Pearce H et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol 2021; 22: 620-626. [Article] [CrossRef] [PubMed] [Google Scholar]
Dan JM, Mateus J, Kato Y et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; 371: eabf4063. [Article] [PubMed] [Google Scholar]
Gaebler C, Wang Z, Lorenzi JCC et al. Evolution of antibody immunity to SARS-CoV-2. Nature 2021; 591: 639-644. [Article] [NASA ADS] [CrossRef] [PubMed] [Google Scholar]
Khehra N, Padda I, Jaferi U et al. Tozinameran (BNT162b2) vaccine: the journey from preclinical research to clinical trials and authorization. AAPS PharmSciTech 2021; 22: 172. [Article] [CrossRef] [PubMed] [Google Scholar]
Shimabukuro T. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine—United States, December 21, 2020—January 10, 2021. , 2021; : 125‒129. [Google Scholar]
Walsh EE, Frenck Jr RW, Falsey AR et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2020; 383: 2439-2450. [Article] [CrossRef] [PubMed] [Google Scholar]
Sahin U, Muik A, Derhovanessian E et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 2020; 586: 594-599. [Article] [NASA ADS] [CrossRef] [PubMed] [Google Scholar]
Deng W, Bao L, Liu J et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 2020; 369: 818-823. [Article] [NASA ADS] [CrossRef] [PubMed] [Google Scholar]
Yu J, Tostanoski LH, Peter L et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 2020; 369: 806-811. [Article] [NASA ADS] [CrossRef] [PubMed] [Google Scholar]
Baumgarth N, Nikolich-Žugich J, Lee FEH et al. Antibody responses to SARS-CoV-2: Let’s stick to known knowns. J Immunol 2020; 205: 2342-2350. [Article] [CrossRef] [PubMed] [Google Scholar]
Wajnberg A, Amanat F, Firpo A et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 2020; 370: 1227-1230. [Article] [CrossRef] [PubMed] [Google Scholar]
Soresina A, Moratto D, Chiarini M et al. Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover. Pediatr Allergy Immunol 2020; 31: 565-569. [Article] [CrossRef] [PubMed] [Google Scholar]
Montero-Escribano P, Matías-Guiu J, Gómez-Iglesias P et al. Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain. Mult Scler Relat Discord 2020; 42: 102185. [Article] [CrossRef] [Google Scholar]
Novi G, Mikulska M, Briano F et al. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?. Mult Scler Relat Discord 2020; 42: 102120. [Article] [CrossRef] [Google Scholar]
Safavi F, Nourbakhsh B, Azimi AR B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Discord 2020; 43: 102195. [Article] [CrossRef] [Google Scholar]
Deng HK, Unutmaz D, KewalRamani VN et al. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 1997; 388: 296-300. [Article] [NASA ADS] [CrossRef] [PubMed] [Google Scholar]
Nie J, Li Q, Wu J et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect 2020; 9: 680-686. [Article] [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
Xie S, Huang J, Qiao Q et al. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. Cancer Immunol Immunother 2018; 67: 1685-1694. [Article] [CrossRef] [PubMed] [Google Scholar]
Long QX, Tang XJ, Shi QL et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26: 1200-1204. [Article] [CrossRef] [PubMed] [Google Scholar]
Ibarrondo FJ, Fulcher JA, Goodman-Meza D et al. Rapid decay of Anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med 2020; 383: 1085-1087. [Article] [CrossRef] [PubMed] [Google Scholar]
Seow J, Graham C, Merrick B et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol 2020; 5: 1598-1607. [Article] [CrossRef] [PubMed] [Google Scholar]
Pisanic N, Randad PR, Kruczynski K et al. COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva. J Clin Microbiol 2020; 59: e02204. [Article] [CrossRef] [PubMed] [Google Scholar]
Sonnenberg GF, Fouser LA, Artis D Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 2011; 12: 383-390. [Article] [CrossRef] [PubMed] [Google Scholar]
Favresse J, Gillot C, Di Chiaro L et al. Neutralizing antibodies in COVID-19 patients and vaccine recipients after two doses of BNT162b2. Viruses 2021; 13: 1364. [Article] [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.